These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29187906)

  • 1. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.
    You R; Cao YS; Huang PY; Chen L; Yang Q; Liu YP; Zou X; Zhang YN; Jiang R; Zhang MX; Duan CY; Lin AH; Hong MH; Chen MY
    Theranostics; 2017; 7(19):4825-4835. PubMed ID: 29187906
    [No Abstract]   [Full Text] [Related]  

  • 2. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.
    Ribassin-Majed L; Marguet S; Lee AWM; Ng WT; Ma J; Chan ATC; Huang PY; Zhu G; Chua DTT; Chen Y; Mai HQ; Kwong DLW; Cheah SL; Moon J; Tung Y; Chi KH; Fountzilas G; Bourhis J; Pignon JP; Blanchard P
    J Clin Oncol; 2017 Feb; 35(5):498-505. PubMed ID: 27918720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.
    Petit C; Blanchard P; Pignon JP; Lueza B
    Syst Rev; 2019 Apr; 8(1):96. PubMed ID: 30987679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06).
    Moon SH; Cho KH; Lee CG; Keum KC; Kim YS; Wu HG; Kim JH; Ahn YC; Oh D; Lee JH
    Strahlenther Onkol; 2016 Jun; 192(6):377-85. PubMed ID: 26972085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
    Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
    J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients.
    Xu C; Zhang LH; Chen YP; Liu X; Zhou GQ; Lin AH; Sun Y; Ma J
    J Cancer; 2017; 8(2):287-297. PubMed ID: 28243333
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020.
    Liang YJ; Liu LT; Li Y; Wang P; Luo MJ; Wen DX; Chen QY; Mai HQ
    JAMA Netw Open; 2022 Mar; 5(3):e220173. PubMed ID: 35234882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
    Fang L; Shi L; Wang W; Hu T; Rao X
    Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.
    Liu F; Jin T; Liu L; Xiang Z; Yan R; Yang H
    PLoS One; 2018; 13(3):e0194733. PubMed ID: 29566078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
    Wang S; Li S; Shen L
    Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.
    Yan M; Kumachev A; Siu LL; Chan KK
    Eur J Cancer; 2015 Aug; 51(12):1570-9. PubMed ID: 26044925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Au KH; Ngan RKC; Ng AWY; Poon DMC; Ng WT; Yuen KT; Lee VHF; Tung SY; Chan ATC; Sze HCK; Cheng ACK; Lee AWM; Kwong DLW; Tam AHP
    Oral Oncol; 2018 Feb; 77():16-21. PubMed ID: 29362121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.